Stockscreener 앱 받기
0.509
16.48%
0.072
시간 외 거래:
.47
-0.039
-7.66%
전일 마감가:
$0.437
열려 있는:
$0.53
하루 거래량:
17.74M
Relative Volume:
30.86
시가총액:
$2.42M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+5.95%
1개월 성능:
+0.02%
6개월 성능:
-15.12%
1년 성능:
+0.00%
1일 변동 폭
$0.3711
$0.55
1주일 범위
$0.37
$0.55
52주 변동 폭
$0.185
$3.00
Entero Therapeutics Inc Stock (ENTO) Company Profile
명칭
Entero Therapeutics Inc
전화
561-589-7020
주소
777 YAMATO ROAD, BOCA RATON
ENTO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
0.509 | 2.42M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Entero Therapeutics Inc 주식(ENTO)의 최신 뉴스
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Entero Therapeutics Delays 10-K Filing - TipRanks
Celiac Disease Pipeline: Pioneering Progress with 25+ Leading - openPR.com
Entero Therapeutics Enters Rescission Deal to Unwind Merger With ImmunogenX - MarketScreener
Entero Therapeutics slips 7%, signs rescission agreement with ImmunogenX - MSN
Strategic Shift: Entero Therapeutics Unwinds Recent Merger and Strengthens Leadership - Stock Titan
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC - Yahoo Finance
Micron (MU) Stock Trades Down, Here Is Why - The Globe and Mail
Johnson & Johnson plans $55 billion in US investments over the next four years - The Globe and Mail
Hogs Close with Weakness on Thursday - The Globe and Mail
Layoff Tracker: Vaxart Cuts 10% of Staff After US Government Orders Vaccine Trial Halt - BioSpace
With outlook uncertain, the Bank of England joins the US Fed in putting interest rates on hold - The Globe and Mail
This Under-the-Radar AI Stock Could Be 1 of the Best Buys for a Recession - The Globe and Mail
Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - The Globe and Mail
European ETFs Gain Momentum as Global Markets Shift - The Globe and Mail
The Unpleasant Truth: The Stock Market Is Still Historically Pricey, Even With the Nasdaq and S&P 500 Recently Falling Into Correction Territory - The Globe and Mail
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Celiac Disease Market Expected to Experience Major Growth - openPR
Significant Contract News Sends Energy Services Company Higher - The Globe and Mail
How Nvidia (NASDAQ:NVDA) Stayed One Step Ahead in the AI Race - The Globe and Mail
Super Micro's International Presence Makes It a Winning Stock - The Globe and Mail
Vicarious Surgical Names Sarah Romano as Finance Chief - MPO-mag
3 Artificial Intelligence (AI) Stocks That Can Weather President Trump's Tariff Storm - The Globe and Mail
Vicarious Surgical appoints Sarah Romano as CFO - MedTech Dive
Can Nvidia’s Stock Keep Climbing as Foxconn Bets Big on AI? - The Globe and Mail
Greif Named 2025 Gallup Exceptional Workplace Award Winner - The Globe and Mail
Vicarious Surgical names Sarah Romano as new CFO By Investing.com - Investing.com Australia
Vicarious Surgical Appoints Sarah Romano as Chief Financial Officer - citybiz
Vicarious Surgical Announces Appointment of Sarah Romano as Chief Financial Officer - Business Wire
Vicarious Surgical names Sarah Romano as new CFO - Investing.com
3 Ways Tech Investors Can Navigate the Artificial Intelligence (AI) Sector Tumble - The Globe and Mail
Stocks Mixed as President Trump Ramps Up Tariffs on Canada - The Globe and Mail
Goldman Sachs: Buy These 2 ‘Rising Star’ Stocks in 2025 - The Globe and Mail
Where Will Coca-Cola Stock Be in 5 Years? - The Globe and Mail
Reflecting On Auto Parts Retailer Stocks’ Q4 Earnings: AutoZone (NYSE:AZO) - The Globe and Mail
Onconetix taps industry veteran as executive chairman amid CEO resignationCincinnati Business Courier - Cincinnati Business Courier
Onconetix names new executive chairman, appoints board member - Investing.com
iHeartMedia (IHRT) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Entero Therapeutics Appoints Richard Paolone as CEO - citybiz
AzurRx BioPharma Receives Approximately $550,000 for its 2020 CIR (French Research Tax Credit) - Marketscreener.com
Entero Therapeutics names Richard Paolone interim CEO - MSN
Entero Therapeutics Appoints Richard Paolone as Interim CEO - TipRanks
Entero Therapeutics names Richard Paolone interim CEO By Investing.com - Investing.com South Africa
Entero Therapeutics Names Richard Paolone Interim CEO - MarketWatch
Entero Therapeutics Names Richard Paolone Interim CEO -February 14, 2025 at 04:25 pm EST - Marketscreener.com
Strategic Leadership Shift: M&A Expert Takes Helm at Entero TherapeuticsKey Details Revealed - StockTitan
Entero Therapeutics, Inc. announced that it has received $2 million in funding from 1396974 B.C. Ltd - Marketscreener.com
Entero Therapeutics Inc (ENTO) Shares Soar Above 1-Year High - The News Heater
Entero Therapeutics Appoints Three New Board Members - citybiz
Entero Therapeutics Inc (ENTO) 재무 분석
Entero Therapeutics Inc (ENTO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):